![]() |
|
|
Vol. 289, Issue 1, 417-426, April 1999
Department of Pharmacology, The antinociceptive action of the alkaloid
cis-8,10-di-n-propyllobelidiol
hydrochloride dehydrate (DPHD), isolated from Siphocampylus verticillatus, given i.p., p.o., i.t., or i.c.v., was assessed in chemical and thermal models of nociception in mice, such as acetic
acid-induced abdominal constriction, formalin- and capsaicin-induced licking, and hot-plate and tail-flick tests. DPHD given by i.p., p.o.,
i.t., or i.c.v. elicited significant and dose-related antinociception. At the ID50 level, DPHD was about 2- to 39-fold more potent
than aspirin and dipyrone, but it was about 14- to 119-fold less potent than morphine. Its analgesic action was reversed by treatment of
animals with p-chlorophenylalanine, naloxone, cyprodime,
naltrindole, nor-binaltrorphimine, L-arginine, or pertussis
toxin. Its action was also modulated by adrenal-gland hormones but was
not affected by
-aminobutyric acid type A or type B antagonist,
bicuculine, or phaclofen, nor was it affected by glibenclamide. DPHD,
given daily for up to 7 days, did not develop tolerance to itself nor did it induce cross-tolerance to morphine. However, animals rendered tolerant to morphine presented cross-tolerance to DPHD. The
antinociception of DPHD was not secondary to its anti-inflammatory
effect, nor was it associated with nonspecific effects such as muscle
relaxation or sedation. DPHD, in contrast to morphine, did not decrease
charcoal meal transit in mice, nor did it inhibit electrical field
stimulation of the guinea pig ileum or mouse vas deferens in vitro.
Thus, DPHD produces dose-dependent and pronounced systemic, spinal, and
supraspinal antinociception in mice, including against the neurogenic
nociception induced by formalin and capsaicin. Its antinociceptive
effect involves multiple mechanisms of action, namely interaction with
µ,
, or
opioid systems, L-arginine-nitric oxide
and serotonin pathways, activation of Gi protein sensitive to pertussis toxin, and modulation by endogenous glucocorticoids.
0022-3565/99/2891-0417$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics